All articles

Pfizer Shelves GLP-1 Obesity Drug After Liver Injury In A Patient

Annexon’s C1q Targeting Of Complement System Could Bring About First Treatment For GBS

Bristol-Myers Squibb Puts Its Hat Into The Ring In Targeting 1st-Line Liver Cancer With OPDIVO-Based Regimen

Opthea Runs Out Of Options With Failed Wet-AMD Studies, Reduces Workforce By 65%

To Get Phase 3 Program Going Tempest Seeks Strategic Alternatives For Amezalpat For Liver Cancer

Bristol-Myers Squibb Nabs FDA Regulatory Wins With OPDIVO And Yervoy Combination For CRC

Photo by Tima Miroshnichenko from Pexels

Rallybio Scraps Maternal Disorder Candidate RLYB212 Shifting Focus To C5 Inhibitor

Photo by Ivan Samkov from Pexels

Rhythm Pharmaceuticals Scores A Win For Obesity Disorder Caused By Impairment Of The Brain

Scroll to Top